TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32779141
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS reminders with medication treatment
Study: 32779141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 4-week medication treatment without reminders
Study: 32011497
Drug: pregabalin +
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin + electro-acupuncture (EA) treatment
Study: 32011497
Drug: pregabalin +
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin + Chuna manual therapy (CMT) treatment
Study: 32011497
Drug: pregabalin administration
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin administration
Study: 32199584
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid treatment within 3 hours after the onset of acute bleeding
Study: 32533015
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene products containing stannous ions (TG)
Study: 33385439
Drug: Ketamine (subanesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (subanesthetic dose)
Study: 35102968
Drug: Probiotic curd
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic curd (Amul's Probiotic Dahi) containing Lactobacillus acidophilus (La5) and Bifidobacterium lactis (Bb12), 100 g two times a day for 21 days
Study: 35728909
Drug: Telepharmacy care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepharmacy care group (customised mobile application and monthly telecommunications)
Study: 32713561
Drug: Intradialytic exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic exercise (twice a week for 8 weeks)
Study: 33059105
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1000 mg in 200 mL normal saline)
Study: 33059105
Drug: Epinephrine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (1 mg in 200 mL normal saline)
Study: 35588372
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of renal replacement therapy (RRT)
Study: 35190080
Drug: MyTeachingPartner (MTP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyTeachingPartner (MTP) coaching; specific dosage not mentioned; duration not specified.
Study: 33416918
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy with vitamin-K antagonists
Study: 33416918
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy with direct oral anticoagulants
Study: 34842775
Drug: Low-Dose External
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose External Beam Radiotherapy (LD-EBRT) 6 × 0.5 Gy
Study: 33328187
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2.5 mg intravitreal bevacizumab and subconjunctival Mitomycin C (group A)
Study: 34004448
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (9 g/day for 2 weeks)
Study: 33148277
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin administration
Study: 34036915
Drug: 50 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg/day levothyroxine for 2 months
Study: 33397249
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg daily for 8 weeks)
Study: 33397249
Drug: Nano-curcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (80 mg daily for 8 weeks)
Study: 33397249
Drug: Placebo (capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsules like curcumin)
Study: 34278433
Drug: On-demand oral
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand oral TDF/emtricitabine for PrEP
Study: 34669884
Drug: Modified tissue-selecting
Normalized name: Tissue Goo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified tissue-selecting therapy stapler combined with complete anal canal preservation surgery
Study: 32349353
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of potato protein isolate (PP) twice daily (1.6 g/kg/d total protein)
Study: 32349353
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (CON) (0.8 g/kg/d total protein)
Study: 35304396
Drug: CRT (50.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT (50.4 Gy with capecitabine) followed by consolidation chemotherapy (six cycles of CapeOx)
Study: 35304396
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (three cycles of CapeOx plus bevacizumab) followed by CRT and consolidation chemotherapy (three cycles of CapeOx)
Study: 36017934
Drug: Local simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local simvastatin (SIM) 2.2 mg in methylcellulose (SIM/MCL)
Study: 35762321
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (4 grams daily)
Study: 33288862
Drug: Midostaurin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin (50 mg twice daily) with standard-of-care (SOC)
Study: 37125529
Drug: sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 200 mg
Study: 35058583
Drug: sacubitril/valsartan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan (both doses)
Study: 35234826
Drug: Gentamicin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin treatment
Study: 34574458
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) products (Angelicae Sinensis Radix, Astragali Radix, Salviae Miltiorrhizae Radix et Rhizoma) administered orally for two weeks
Study: 34663787
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy
Study: 34763615
Drug: Brief Relational
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Relational Therapy (BRT)
Study: 35150156
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.9 mg daily for 6 months
Study: 32188111
Drug: Q10Vital® water-soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q10Vital® water-soluble CoQ10 syrup (investigational product)
Study: 32188111
Drug: Ubiquinol capsules
Normalized name: ubiquinol Oral Capsule
DrugBank: Ubiquinol (DB11340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol capsules (comparative product)
Study: 32188111
Drug: Ubiquinone capsules
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubiquinone capsules (standard product)
Study: 32202330
Drug: 3 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day Zataria multiflora extract (Z3) for 2 months
Study: 32202330
Drug: 6 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg/day Zataria multiflora extract (Z6) for 2 months
Study: 32107487
Drug: TIVA (target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (target-controlled infusion of propofol and remifentanil)
Study: 32107487
Drug: BGA (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGA (continuous remifentanil infusion and sevoflurane inhalation)
Study: 32522698
Drug: Epinephrine ≥3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine ≥3 mg
Study: 32522698
Drug: Epinephrine <3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine <3 mg
Study: 37306651
Drug: Transcatheter edge‐to‐edge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter edge‐to‐edge repair (TEER) with MitraClip plus guideline‐directed medical therapy (GDMT)
Study: 35503145
Drug: Mindfulness practice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness practice at least twice a week
Study: 34779137
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy with 5% lavender oil
Study: 34779137
Drug: Placebo massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo massage therapy with baby oil
Study: 35285912
Drug: IRF-40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRF-40 (40 mg iron/d)
Study: 35285912
Drug: IRF-20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRF-20 (20 mg iron/d)
Study: 35596636
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 and B2 urinary excretion
Study: 33038271
Drug: 0.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 g/kg alcohol dose
Study: 33619178
Drug: Probability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probability of vaccine efficacy (50%, 70%, or 90%)
Study: 33619178
Drug: Announcement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Announcement of vaccines being 95% effective
Study: 36066264
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula (HFNC) therapy
Study: 36066264
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy without HFNC
Study: 33121372
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 µg
Study: 36368914
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg·kg‐1 intravenously)
Study: 35342769
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (canagliflozin) 100 mg/day
Study: 35342769
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (empagliflozin) 10 mg/day
Study: 35342769
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (ertugliflozin) 5 mg/day
Study: 35342769
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (ipragliflozin) 50 mg/day
Study: 35342769
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (luseogliflozin) 2.5 mg/day
Study: 35342769
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (tofogliflozin) 20 mg/day
Study: 32168273
Drug: Pediatric orders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric orders requiring drug formulation manipulation (n=3925)
Study: 32168273
Drug: Adult orders
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult orders requiring drug formulation manipulation (n=1301)
Study: 33857028
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN) 50 mg
Study: 33164066
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by chemoradiotherapy (Arm B)
Study: 33164066
Drug: Chemoradiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy with concurrent S-1 (Arm A)
Study: 32301388
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with low-dose ketamine (0.25mg/kg propofol + 0.15mg/kg ketamine)
Study: 35409646
Drug: Individualised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised exercise prescription (n = 24)
Study: 35409646
Drug: Standardised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised exercise prescription (n = 25)
Study: 36229975
Drug: Baseline sCD163
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline sCD163 ≤ 500 pg/ml
Study: 33742252
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen (carboxy therapy + intralesional corticosteroids)
Study: 32166395
Drug: Unilateral subcostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral subcostal transversus abdominis plane (TAP) block with 20 mL 0.25% bupivacaine
Study: 32166395
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infiltration at port sites with 20 mL 0.25% bupivacaine
Study: 34133820
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg every 8 hours for 5 days)
Study: 34133820
Drug: Ketorolac (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (10 mg every 8 hours for 5 days)
Study: 34133820
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg every 8 hours for 5 days)
Study: 34541612
Drug: Sorafenib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib alone or following selective internal radiation therapy (SIRT)
Study: 33861441
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg) and famotidine (40 mg) daily for 1 month
Study: 33861441
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and famotidine (40 mg)
Study: 36910899
Drug: Intrarectal local
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal local anesthesia with 20 mL of heated (40°C) 2% lidocaine gel (n = 50)
Study: 33933916
Drug: BVDV antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVDV antibody competitive-ELISA assay
Study: 35803469
Drug: Camostat mesylate
Normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesylate 300 mg three times daily in a fasted state
Study: 32229229
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical training (PT) group, n = 22, received home‐based supervised muscle strength and endurance training in twice‐weekly 60‐min sessions for 12 weeks
Study: 33536190
Drug: PI3Kβ inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI3Kβ inhibitor AZD8186
Study: 33536190
Drug: AKT inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT inhibitor MK-2206
Study: 34007050
Drug: MEK inhibitor
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK inhibitor selumetinib
Study: 34978662
Drug: Hybrid decision
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid decision support system using Artificial Intelligence for low-risk prescriptions
Study: 34978662
Drug: High-risk prescriptions
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk prescriptions
Study: 34195574
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg per day)
Study: 35705502
Drug: DIZ101 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIZ101 (intravenous infusion of levodopa/carbidopa)
Study: 35705502
Drug: DIZ102 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIZ102 (subcutaneous infusion of levodopa/carbidopa)
Study: 35705502
Drug: LCIG (intestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCIG (intestinal infusion of levodopa/carbidopa)
Study: 35705502
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (DIZ101, DIZ102, LCIG)
Study: 35475975
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) decoction, administered twice a day for at least 3 and up to 24 months.
Study: 34266456
Drug: Leukocyte and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte and platelet-rich fibrin (L-PRF) applied on ulcer beds during twice-weekly dressing changes
Study: 34266456
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (saline dressings only) during twice-weekly dressing changes
Study: 35266830
Drug: hNB001 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: hNB001 (20 mg to 400 mg)
Study: 34559684
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil therapy (3% concentration)
Study: 32014581
Drug: Violet LED
Normalized name: acid violet 43
Approvals — FDA: no, EMA: no, PMDA: no
Description: Violet LED (VL) irradiation for 30 min, twice per week for three weeks (totaling six sessions)
Study: 35399071
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction (MBSR) group training, 8 sessions weekly (120-min/session) for 2 months
Study: 32839527
Drug: Minocycline 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 150 mg (twice daily)
Study: 34987129
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg, bid)
Study: 34987129
Drug: Control (ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ACEI/ARB and β‐receptor blockers)
Study: 33849138
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care + music therapy for 60min
Study: 33093340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cues to medication availability)
Study: 39415182
Drug: Attachment-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based family therapy (ABFT)
Study: 32228168
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to treatment
Study: 32681402
Drug: Computer-generated medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-generated medication recommendations
Study: 39679749
Drug: Small-Quantity Lipid-Based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNS)
Study: 36053828
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (test group)
Study: 33998210
Drug: CPC loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC loaded with rhBMP‐2 combined with CPC loaded with antibiotic
Study: 33998210
Drug: CPC loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC loaded with antibiotic
Study: 33215209
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg/day)
Study: 32493662
Drug: Continuous magnesium
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous magnesium infusion (10 mmol loading dose of magnesium sulphate followed by 3 mmol/h for up to 96 hours)
Study: 32493662
Drug: Continuous magnesium
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous magnesium infusion
Study: 34432203
Drug: Xuezhikang (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (1200 mg/d, orally)
Study: 34432203
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/d, orally)
Study: 34632426
Drug: Prophylactic azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic azithromycin (1 g orally) once at baseline
Study: 34923216
Drug: WATSU therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WATSU therapy combined with land-based therapy
Study: 34923216
Drug: Land-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based therapy (Control Group)
Study: 33107945
Drug: Catheter ablation
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter ablation combined with vein of Marshall ethanol infusion
Study: 34592949
Drug: Epinephrine (BOSMIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (BOSMIN® SOLUTION 0.1%, diluted to 0.02%)
Study: 34592949
Drug: Tramazoline (TRAMAZOLIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramazoline (TRAMAZOLIN Nasal Solution 0.118%)
Study: 35759281
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for headache (8 sessions)
Study: 35759281
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy for PTSD (12 sessions)
Study: 35759281
Drug: Treatment per
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment per usual (Control)
Study: 33568368
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral melatonin nightly for 12 weeks
Study: 33568368
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral melatonin
Study: 33023498
Drug: Anti-retroviral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-retroviral treatment (ART)
Study: 34789700
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine injection
Study: 36103386
Drug: Alfaxalone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (5 mg/kg, IV) + Physiologic saline (0.5 mL, IM)